Product Name:4-Quinazolinamine, 6-(3-aminopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxy-
IUPAC Name:6-(3-aminopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
| Packing Unit | Available Stock | Price($) | Quantity |
|---|---|---|---|
| CM633422-50mg | in stock | IJƓǪ |
|
| CM633422-100mg | in stock | ŗƥǪ |
|
| CM633422-250mg | in stock | ľǪůIJ |
|
| CM633422-1g | in stock | ľůŗIJ |
|
|
|||
| Product Overview |
Linkable gefitinib analogue (LGA) is a novel drug developed by scientists to target cancer cells. It is a derivative of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been used to treat non-small cell lung cancer (NSCLC). LGA is designed to be more effective than gefitinib in targeting cancer cells and has been studied extensively in laboratory experiments. |
| Synthesis and Application |
The synthesis of Linkable gefitinib analogue involves a series of chemical reactions. First, gefitinib is reacted with a linker molecule, such as a cyclic anhydride or a thiol-containing compound, which forms an amide or thioester bond. This bond is then reacted with a target molecule, such as an antibody or a peptide, to form a covalent bond. Finally, the linker molecule is cleaved, releasing the Linkable gefitinib analogue molecule. This method has been used to synthesize various derivatives of gefitinib, including Linkable gefitinib analogue. Linkable gefitinib analogue has been studied extensively in laboratory experiments to determine its efficacy in targeting cancer cells. It has been used in a variety of cell-based assays to test the effects of the drug on tumor cell proliferation, invasion, and migration. It has also been used in animal models to study the drug’s effects on tumor growth and metastasis. Additionally, Linkable gefitinib analogue has been used in clinical trials to evaluate its efficacy in treating NSCLC. |
| Future Directions |
There are several potential future directions for the use of Linkable gefitinib analogue. It could be used in combination with other drugs to further enhance its efficacy in targeting cancer cells. Additionally, it could be used in combination with immunotherapies to target tumor cells more effectively. Furthermore, it could be used in combination with other drugs to target other types of cancer, such as breast, ovarian, and colorectal cancer. Finally, it could be used to target other types of diseases, such as autoimmune disorders and neurological diseases. |
Search 
+86 21 5895 0110 
